These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35921025)

  • 1. Growth dynamics of breast cancer stem cells: effects of self-feedback and EMT mechanisms.
    Pang L; Liu S; Zhao Z; Tian T; Zhang X; Li Q
    Theory Biosci; 2022 Sep; 141(3):297-311. PubMed ID: 35921025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling of Cancer Stem Cell State Transitions Predicts Therapeutic Response.
    Sehl ME; Shimada M; Landeros A; Lange K; Wicha MS
    PLoS One; 2015; 10(9):e0135797. PubMed ID: 26397099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer.
    Zhang L; Xu L; Zhang F; Vlashi E
    Cell Cycle; 2017 Apr; 16(8):737-745. PubMed ID: 27753527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts.
    Liu S; Cong Y; Wang D; Sun Y; Deng L; Liu Y; Martin-Trevino R; Shang L; McDermott SP; Landis MD; Hong S; Adams A; D'Angelo R; Ginestier C; Charafe-Jauffret E; Clouthier SG; Birnbaum D; Wong ST; Zhan M; Chang JC; Wicha MS
    Stem Cell Reports; 2014 Jan; 2(1):78-91. PubMed ID: 24511467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Primary Breast Cancer Stem Cells Are Characterized by Epithelial-Mesenchymal Plasticity.
    Strietz J; Stepputtis SS; Follo M; Bronsert P; Stickeler E; Maurer J
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance.
    Mallini P; Lennard T; Kirby J; Meeson A
    Cancer Treat Rev; 2014 Apr; 40(3):341-8. PubMed ID: 24090504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer stem cells, EMT and therapeutic targets.
    Kotiyal S; Bhattacharya S
    Biochem Biophys Res Commun; 2014 Oct; 453(1):112-6. PubMed ID: 25261721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary study of the role of extracellular -5'- nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition.
    Yu J; Liao X; Li L; Lv L; Zhi X; Yu J; Zhou P
    In Vitro Cell Dev Biol Anim; 2017 Feb; 53(2):132-140. PubMed ID: 27670764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
    BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
    Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.
    May CD; Sphyris N; Evans KW; Werden SJ; Guo W; Mani SA
    Breast Cancer Res; 2011 Feb; 13(1):202. PubMed ID: 21392411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SURVIVIN as a marker for quiescent-breast cancer stem cells-An intermediate, adherent, pre-requisite phase of breast cancer metastasis.
    Siddharth S; Das S; Nayak A; Kundu CN
    Clin Exp Metastasis; 2016 Oct; 33(7):661-75. PubMed ID: 27411340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
    Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
    Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells.
    Devarajan E; Song YH; Krishnappa S; Alt E
    Int J Cancer; 2012 Sep; 131(5):1023-31. PubMed ID: 22038895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound targeted microbubble destruction-mediated SOCS3 attenuates biological characteristics and epithelial-mesenchymal transition (EMT) of breast cancer stem cells.
    Tang X; Hao N; Zhou Y; Liu Y
    Bioengineered; 2022 Feb; 13(2):3896-3910. PubMed ID: 35109743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Breast Cancer Stem Cells.
    Zhang L; Chen W; Liu S; Chen C
    Int J Biol Sci; 2023; 19(2):552-570. PubMed ID: 36632469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer.
    Shi R; Liu L; Wang F; He Y; Niu Y; Wang C; Zhang X; Zhang X; Zhang H; Chen M; Wang Y
    Cell Signal; 2020 Dec; 76():109810. PubMed ID: 33069797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways.
    Cruz-Lozano M; González-González A; Marchal JA; Muñoz-Muela E; Molina MP; Cara FE; Brown AM; García-Rivas G; Hernández-Brenes C; Lorente JA; Sanchez-Rovira P; Chang JC; Granados-Principal S
    Eur J Nutr; 2019 Dec; 58(8):3207-3219. PubMed ID: 30460610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.